Dublin Institute of Technology
Trending Articles
Related Content
Regulatory
Post-Brexit biosimilar development in Europe: impacts and challenges
In March 2017, the United Kingdom (UK) triggered Article 50 of the Treaty on European Union (EU) and announced its intention to withdraw from the EU; with the final stages of the EU-UK negotiations scheduled for October 2018, concrete details of the full implications of what Brexit will mean for the biopharmaceutical sector remain unclear